Try our beta test site

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Icahn School of Medicine at Mount Sinai
Sponsor:
Information provided by (Responsible Party):
Joshua Brody, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT01976585
First received: October 30, 2013
Last updated: September 13, 2016
Last verified: September 2016
  Purpose

Our recent trials combining local radiotherapy with intratumoral administration of TLR agonists - referred to as 'in situ vaccination' - for patients with low-grade lymphoma demonstrated safety, induction of anti-tumor CD8 T cell responses and partial and complete remissions of patients' non-irradiated sites of disease with complete remissions lasting from months to more than three years.

This iteration of the in situ vaccine approach builds on our prior work in ways that should improve its efficacy, by adding Flt3L and changing the toll-like receptors (TLR) agonist to poly-ICLC -an optimal TLR agonist for the type of dendritic cells (DC) recruited by Flt3L. The vaccine is thus in 3 phases:

  1. intratumoral Flt3L administration recruits DC to the tumor
  2. low-dose radiotherapy to release tumor antigens
  3. intratumoral poly-ICLC administration activates tumor-antigen loaded DC

Condition Intervention Phase
Low-Grade B-cell Lymphoma
Drug: rhuFlt3L/CDX-301
Drug: Poly-ICLC
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Intratumoral Injection of rhuFlt3L/CDX-301 and Poly-ICLC in Combination With Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas

Resource links provided by NLM:


Further study details as provided by Icahn School of Medicine at Mount Sinai:

Primary Outcome Measures:
  • response rate [ Time Frame: week 12 ]
    Overall objective response rate at time of best response as defined by International Harmonization (Cheson) Criteria.


Secondary Outcome Measures:
  • safety profile [ Time Frame: week 1 ]
    Patient reported and clinical observation of adverse events, including changes in physical examination, peripheral blood hematology and serum chemistry

  • safety profile [ Time Frame: week 2 ]
    Patient reported and clinical observation of adverse events, including changes in physical examination, peripheral blood hematology and serum chemistry

  • safety profile [ Time Frame: week 4 ]
    Patient reported and clinical observation of adverse events, including changes in physical examination, peripheral blood hematology and serum chemistry

  • safety profile [ Time Frame: week 6 ]
    Patient reported and clinical observation of adverse events, including changes in physical examination, peripheral blood hematology and serum chemistry

  • safety profile [ Time Frame: week 8 ]
    Patient reported and clinical observation of adverse events, including changes in physical examination, peripheral blood hematology and serum chemistry

  • safety profile [ Time Frame: week 12 ]
    Patient reported and clinical observation of adverse events, including changes in physical examination, peripheral blood hematology and serum chemistry

  • tumor-specific immune response [ Time Frame: baseline ]
    Pre- to post-treatment induction of systemic (peripheral blood) tumor-specific immune response.

  • tumor-specific immune response [ Time Frame: week 2 ]
    Pre- to post-treatment induction of systemic (peripheral blood) tumor-specific immune response.

  • tumor-specific immune response [ Time Frame: week 4 ]
    Pre- to post-treatment induction of systemic (peripheral blood) tumor-specific immune response.

  • tumor-specific immune response [ Time Frame: week 6 ]
    Pre- to post-treatment induction of systemic (peripheral blood) tumor-specific immune response.

  • tumor-specific immune response [ Time Frame: week 8 ]
    Pre- to post-treatment induction of systemic (peripheral blood) tumor-specific immune response.

  • tumor-specific immune response [ Time Frame: week 12 ]
    Pre- to post-treatment induction of systemic (peripheral blood) tumor-specific immune response.


Estimated Enrollment: 30
Study Start Date: December 2013
Estimated Study Completion Date: November 2018
Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rhuFlt3L/CDX-301
intratumoral injections on days 1-5 and 8-11. and Poly-ICLC intratumoral injection weekly, weeks 2-8
Drug: rhuFlt3L/CDX-301

rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.

RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7.

Drug: Poly-ICLC
Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
Other Name: Hiltonol

Detailed Description:

Lymphomas comprise the 5th most common cancer in the U.S. with approximately 80,000 new cases diagnosed in the U.S. each year. Low-grade B-cell lymphomas are the most prevalent subtype amongst these and are considered incurable with standard therapies. Chemotherapy and monoclonal antibody therapy induce temporary remissions, though disease generally recurs, becomes progressively more resistant to therapy and ultimately therapy-resistant. Standard therapies prolong survival, though there is no standard of care regarding when to initiate therapy (versus observation) or the optimal sequence of different therapies. Novel therapies are needed with distinct mechanisms and with greater tolerability profiles. Immunotherapy has a long precedent of being able to cure low-grade lymphomas with allogeneic transplant being curative in a proportion of chemo-refractory patients, though the morbidity of this procedure reduces its broader utilization.

Previously, we completed four trials combining local radiotherapy (a standard of care for these diseases) with intratumoral administration of TLR agonists - an approach we refer to as 'in situ vaccination' for patients with previously untreated or relapsed/refractory low-grade lymphoma. We demonstrated safety, induction of anti-tumor CD8 T cell responses and partial and complete remissions of patients' non-irradiated sites of disease.1, 2 The most recent trials compared previously untreated versus relapsed/refractory patients receiving the same therapy and observed superior responses in the former group, presumably due to immunosuppressive effects of prior treatments in the latter group. The in situ vaccine is premised on pre-clinical data showing this approach to be superior to systemic TLR agonist delivery3 and our clinical results reproduce this finding; in situ vaccination yields superior response rates as compared to trials of systemic TLR agonist therapy for lymphoma.4

This iteration of the in situ vaccine approach builds on our prior work in ways that should improve its efficacy, by making two changes to the prior approach:

  1. intratumoral administration of rhuFlt3L/CDX-301 to recruit dendritic cells to the tumor site
  2. intratumoral administration of poly-ICLC. Flt3L has been safely administered to patients with lymphoma5 and -pre-clinically- has been shown to induce tumor leukocyte infiltration and regression of lymphoma tumors.6, 7 A total of 36 healthy volunteers and 294 cancer patients were treated including only industry-sponsored studies with the prior formulation of this agent (AMG 949) with excellent tolerability and 30 healthy volunteers were recently treated with the current formulation (CDX-301), again with excellent tolerability.

Poly-ICLC has been safely administered to patients with lymphoma8 and -pre-clinically- has been shown to induce natural killer (NK) cell cytolytic activity and regression of lymphoma tumors.9-11 Over 600 healthy volunteers and cancer patients in 17 trials have been treated with comparable doses of poly-ICLC as that used here with excellent tolerability.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biopsy-confirmed low-grade B-cell lymphoma or cutaneous T cell lymphoma; specifically, follicular grade 1, 2, or 3A, marginal zone or small lymphocytic lymphoma, or mycosis fungoides of any initial stage. Patients in cohort A must have had no prior systemic therapy and patients in cohort B must be relapsed/refractory after at least one prior systemic therapy.
  • Patients must have at least one site of disease that is accessible for intratumoral injection percutaneously (e.g. inguinal, axillary, cervical, or subcutaneous).
  • Tumor specimens must be available for immunological studies, either from a previous biopsy or a new biopsy obtained before the initiation Day 1 of the study.
  • Patients must have measurable disease other than the injection site or biopsy site, i.e. greater than 1.5 cm bi-dimensionally on standard computed tomography imaging.
  • ECOG Performance Status of 1 or better (corresponds to Karnofsky Performance Status (KPS) of ≥ 70)
  • Patients must be 18 years of age or older.
  • Adequate bone marrow function: WBC ≥ 2,000/μL; platelet count ≥ 75,000/mm3; ANC ≥ 1000/μL.
  • Adequate renal function: serum creatinine ≤ 2.0mg/dL.
  • Adequate hepatic function: bilirubin ≤ 1.5 mg/dL; SGOT/SGPT < 3 x upper limit of normal
  • Required wash out periods for prior therapy (for cohort B):

    1. Topical therapy: 2 weeks
    2. Chemotherapy: 4 weeks
    3. Radiotherapy: 4 weeks
    4. Other investigational therapy: 4 weeks
    5. Rituximab: 12 weeks
  • Patients of reproductive potential and their partners must agree to use an effective (> 90% reliability) form of contraception during the study and for 4 weeks following the last study drug administration.
  • Women of reproductive potential must have negative urine pregnancy test.
  • Life expectancy greater than 4 months.
  • Able to comply with the treatment schedule.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Pre-existing autoimmune or antibody -mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, history of uveitis. Patients with controlled thyroid disease, or the presence of auto-antibodies without clinical autoimmune disease, are permitted on study.
  • Known history of human immunodeficiency virus (HIV).
  • Patients with active infection.
  • Known CNS metastases.
  • Prior malignancy (active within 5 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix.
  • History of allergic reactions to compounds of similar composition to either CDX-301 or poly-ICLC.
  • Current anticoagulant therapy. (ASA ≤ 325 mg per day is allowed.).
  • Significant cardiovascular disease (i.e. NYHA class 3 congestive heart failure; myocardial infarction with the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).
  • Pregnant or lactating.
  • Any other medical history, including laboratory abnormalities, deemed by the investigator to be likely to interfere with their participation in the study, or to interfere with the interpretation of the results.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01976585

Contacts
Contact: Fiby George 212-824-7822 fiby.george@mssm.edu

Locations
United States, New York
Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
Principal Investigator: Joshua Brody, MD         
Sponsors and Collaborators
Joshua Brody
Investigators
Principal Investigator: Joshua Brody, MD Icahn School of Medicine at Mount Sinai
  More Information

Publications:

Responsible Party: Joshua Brody, Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT01976585     History of Changes
Other Study ID Numbers: GCO 13-1347
Study First Received: October 30, 2013
Last Updated: September 13, 2016

Keywords provided by Icahn School of Medicine at Mount Sinai:
Intratumoral injections
rhuFlt3L
Flt3L
CDX-301
Vaccine
Poly-ICLC
iNHL
TLR3
Low-Grade B-cell Lymphoma
Follicular
Marginal Zone
SLL
Small lymphocytic

Additional relevant MeSH terms:
Lymphoma
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Flt3 ligand protein
Poly ICLC
Poly I-C
Carboxymethylcellulose Sodium
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Radiation-Protective Agents
Protective Agents
Interferon Inducers
Laxatives
Gastrointestinal Agents
Antiviral Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on March 28, 2017